PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis

Research output: Contribution to journalArticle

Abstract

Gynecologic cancers represent a major global healthcare problem since they are associated with a significant mortality and morbidity. Over the last decade, considerable efforts have been spent in the development and optimization of novel diagnostic modalities to achieve an early diagnosis, aid in choosing appropriate treatment, improving long term surveillance, with the ultimate goal of increasing survival of gynecologic cancer patients. A growing body of evidence defines PET/CT as one of the most powerful tools for tumor, nodal and metastasis (TNM) cancer staging both in pre-treatment and in post treatment follow-up settings. At any phase of cancer evaluation, detection of metastasis represents one of the most critical impediments to the cure of tumor; traditional diagnostic imaging modalities, such as computed tomography (CT), are frequently found to inadequately stage the tumor, based on subsequent outcomes. As a consequence, patients may undergo pointless surgery for disease that could be treated with local medical therapies. In the setting of restaging, the ability to describe primary lesion, lymph nodes, possible metastases to peritoneum, bone, liver, lungs and brain renders PET/CT a potential alternative for a series of tests, including bone scanning, MRI or ultrasound, diagnostic CT, lymph node surgical sampling, that need to be used in combination in order to obtain a level of clinical confidence. In this review, we describe, the theoretical advantage and prognostic implications of PET/CT in the management of gynecologic cancer patients.

Original languageEnglish
Pages (from-to)84-98
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Volume83
Issue number1
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Tomography
Neoplasms
Neoplasm Metastasis
Lymph Nodes
Bone and Bones
Neoplasm Staging
Peritoneum
Diagnostic Imaging
Therapeutics
Early Diagnosis
Ultrasonography
Morbidity
Delivery of Health Care
Lung
Survival
Mortality
Liver
Brain

Keywords

  • Cervical cancer
  • Endometrial cancer
  • FDG-PET/CT
  • Gyneacologic malignancies
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

@article{8046bb0a570047c0b9bd29bdf9082857,
title = "PET/CT imaging in gynecologic malignancies: A critical overview of its clinical impact and our retrospective single center analysis",
abstract = "Gynecologic cancers represent a major global healthcare problem since they are associated with a significant mortality and morbidity. Over the last decade, considerable efforts have been spent in the development and optimization of novel diagnostic modalities to achieve an early diagnosis, aid in choosing appropriate treatment, improving long term surveillance, with the ultimate goal of increasing survival of gynecologic cancer patients. A growing body of evidence defines PET/CT as one of the most powerful tools for tumor, nodal and metastasis (TNM) cancer staging both in pre-treatment and in post treatment follow-up settings. At any phase of cancer evaluation, detection of metastasis represents one of the most critical impediments to the cure of tumor; traditional diagnostic imaging modalities, such as computed tomography (CT), are frequently found to inadequately stage the tumor, based on subsequent outcomes. As a consequence, patients may undergo pointless surgery for disease that could be treated with local medical therapies. In the setting of restaging, the ability to describe primary lesion, lymph nodes, possible metastases to peritoneum, bone, liver, lungs and brain renders PET/CT a potential alternative for a series of tests, including bone scanning, MRI or ultrasound, diagnostic CT, lymph node surgical sampling, that need to be used in combination in order to obtain a level of clinical confidence. In this review, we describe, the theoretical advantage and prognostic implications of PET/CT in the management of gynecologic cancer patients.",
keywords = "Cervical cancer, Endometrial cancer, FDG-PET/CT, Gyneacologic malignancies, Ovarian cancer",
author = "Palma, {Maurizia Dalla} and Michele Gregianin and Pasquale Fiduccia and Laura Evangelista and Cervino, {Anna Rita} and Giorgio Saladini and Lucia Borgato and Nicoletto, {Maria Ornella} and Vittorina Zagonel",
year = "2012",
month = "7",
doi = "10.1016/j.critrevonc.2011.10.002",
language = "English",
volume = "83",
pages = "84--98",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - PET/CT imaging in gynecologic malignancies

T2 - A critical overview of its clinical impact and our retrospective single center analysis

AU - Palma, Maurizia Dalla

AU - Gregianin, Michele

AU - Fiduccia, Pasquale

AU - Evangelista, Laura

AU - Cervino, Anna Rita

AU - Saladini, Giorgio

AU - Borgato, Lucia

AU - Nicoletto, Maria Ornella

AU - Zagonel, Vittorina

PY - 2012/7

Y1 - 2012/7

N2 - Gynecologic cancers represent a major global healthcare problem since they are associated with a significant mortality and morbidity. Over the last decade, considerable efforts have been spent in the development and optimization of novel diagnostic modalities to achieve an early diagnosis, aid in choosing appropriate treatment, improving long term surveillance, with the ultimate goal of increasing survival of gynecologic cancer patients. A growing body of evidence defines PET/CT as one of the most powerful tools for tumor, nodal and metastasis (TNM) cancer staging both in pre-treatment and in post treatment follow-up settings. At any phase of cancer evaluation, detection of metastasis represents one of the most critical impediments to the cure of tumor; traditional diagnostic imaging modalities, such as computed tomography (CT), are frequently found to inadequately stage the tumor, based on subsequent outcomes. As a consequence, patients may undergo pointless surgery for disease that could be treated with local medical therapies. In the setting of restaging, the ability to describe primary lesion, lymph nodes, possible metastases to peritoneum, bone, liver, lungs and brain renders PET/CT a potential alternative for a series of tests, including bone scanning, MRI or ultrasound, diagnostic CT, lymph node surgical sampling, that need to be used in combination in order to obtain a level of clinical confidence. In this review, we describe, the theoretical advantage and prognostic implications of PET/CT in the management of gynecologic cancer patients.

AB - Gynecologic cancers represent a major global healthcare problem since they are associated with a significant mortality and morbidity. Over the last decade, considerable efforts have been spent in the development and optimization of novel diagnostic modalities to achieve an early diagnosis, aid in choosing appropriate treatment, improving long term surveillance, with the ultimate goal of increasing survival of gynecologic cancer patients. A growing body of evidence defines PET/CT as one of the most powerful tools for tumor, nodal and metastasis (TNM) cancer staging both in pre-treatment and in post treatment follow-up settings. At any phase of cancer evaluation, detection of metastasis represents one of the most critical impediments to the cure of tumor; traditional diagnostic imaging modalities, such as computed tomography (CT), are frequently found to inadequately stage the tumor, based on subsequent outcomes. As a consequence, patients may undergo pointless surgery for disease that could be treated with local medical therapies. In the setting of restaging, the ability to describe primary lesion, lymph nodes, possible metastases to peritoneum, bone, liver, lungs and brain renders PET/CT a potential alternative for a series of tests, including bone scanning, MRI or ultrasound, diagnostic CT, lymph node surgical sampling, that need to be used in combination in order to obtain a level of clinical confidence. In this review, we describe, the theoretical advantage and prognostic implications of PET/CT in the management of gynecologic cancer patients.

KW - Cervical cancer

KW - Endometrial cancer

KW - FDG-PET/CT

KW - Gyneacologic malignancies

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84862140807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862140807&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.10.002

DO - 10.1016/j.critrevonc.2011.10.002

M3 - Article

C2 - 22245509

AN - SCOPUS:84862140807

VL - 83

SP - 84

EP - 98

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -